Faricimab

Faricimab is a humanized bispecific monoclonal antibody used in ophthalmology to treat several retinal vascular disorders. It targets two signaling proteins, vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2), which contribute to abnormal blood vessel growth, vascular leakage, inflammation, and retinal swelling. By inhibiting both pathways, faricimab reduces abnormal vascular permeability and pathological angiogenesis and helps improve vascular stability and control fluid accumulation in the retina. The medicine is administered by intravitreal injection directly into the vitreous cavity of the affected eye by a qualified ophthalmologist experienced in intraocular injections. Faricimab is clinically important because retinal diseases such as wet age-related macular degeneration and diabetic macular edema can require repeated anti-VEGF treatment over extended periods. Its dual mechanism provides an additional approach to managing these conditions and may allow individualized treatment intervals in appropriate patients. Faricimab is approved for adults with neovascular or wet age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. It received its initial United States approval in 2022, while European Union marketing authorization was granted in 2022. Its development was supported by phase III clinical programs including TENAYA and LUCERNE for neovascular age-related macular degeneration and YOSEMITE and RHINE for diabetic macular edema.

Faricimab was developed as a bispecific antibody designed to inhibit both VEGF-A and Ang-2, two pathways involved in retinal vascular instability, leakage, inflammation, and abnormal blood vessel formation. The United States Food and Drug Administration granted the initial approval of faricimab-svoa in January 2022 for neovascular or wet age-related macular degeneration and diabetic macular edema. The FDA subsequently added macular edema following retinal vein occlusion to the approved indications in October 2023 and updated the RVO dosing information in April 2026 to support continued treatment beyond the initial six months. In the European Union, Vabysmo received centralized marketing authorization in September 2022 for neovascular age-related macular degeneration and diabetic macular edema, with the indication later expanded to macular edema secondary to retinal vein occlusion. The clinical development program included the TENAYA and LUCERNE phase III trials for neovascular age-related macular degeneration and the YOSEMITE and RHINE phase III trials for diabetic macular edema. These studies evaluated visual outcomes, retinal anatomy, safety, and the potential for individualized extended dosing intervals.

Faricimab is used in adults for neovascular or wet age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion, including branch and central retinal vein occlusion. It is administered directly into the affected eye and treatment selection depends on the underlying retinal disease, visual acuity, retinal fluid or edema, and findings from ocular imaging. Faricimab is an intravitreal VEGF-A and Ang-2 inhibitor and is generally used as an ocular therapy rather than systemic treatment. For neovascular age-related macular degeneration and diabetic macular edema, dosing intervals can be individualized according to disease activity and treatment response. For macular edema following retinal vein occlusion, treatment begins with regular intravitreal injections and ongoing treatment is determined by clinical assessment and retinal findings. Faricimab may be used as an alternative to other intravitreal anti-VEGF therapies when considered appropriate by the treating ophthalmologist.

Faricimab is administered by intravitreal injection at a dose of 6 mg in 0.05 mL by a qualified physician. For neovascular age-related macular degeneration, the recommended regimen begins with four monthly injections followed by optical coherence tomography and visual acuity assessments to determine subsequent dosing intervals. The U.S. prescribing information provides individualized schedules based on disease activity, with some patients requiring continued monthly treatment and others receiving longer intervals. For diabetic macular edema, faricimab may be administered monthly for at least four doses followed by interval adjustment according to central subfield thickness and visual acuity, or monthly for the first six doses followed by dosing every eight weeks. For macular edema following retinal vein occlusion, the recommended dose is 6 mg every four weeks, with continued treatment determined by disease activity and clinical assessment. Treatment duration is individualized according to visual response, retinal anatomy, disease activity, and tolerability.

Common side effects of faricimab include cataract, conjunctival hemorrhage, increased intraocular pressure, eye pain, vitreous floaters, blurred or reduced vision, and other ocular discomfort or inflammatory symptoms. Conjunctival hemorrhage can appear as a visible area of redness on the white part of the eye following injection. Temporary changes in vision or discomfort may occur after an intravitreal procedure. The frequency and severity of adverse effects can vary according to the underlying retinal disease, injection frequency, previous ocular treatments, and individual patient factors. Because some symptoms following an eye injection can indicate a serious complication, patients should not assume that persistent or worsening eye pain, redness, light sensitivity, new floaters, or reduced vision are routine effects and should seek prompt ophthalmic assessment when these occur.

Important risks associated with faricimab include endophthalmitis, retinal detachment, increased intraocular pressure, retinal vasculitis, retinal vascular occlusion, hypersensitivity reactions, and arterial thromboembolic events. Intravitreal injections can introduce a risk of serious ocular infection or retinal complications, making strict aseptic technique essential. Faricimab is contraindicated in patients with ocular or periocular infection, active intraocular inflammation, or known hypersensitivity to faricimab or its components. Intraocular pressure may rise temporarily after injection and should be monitored and managed when clinically necessary. Retinal vasculitis and retinal vascular occlusion, typically associated with intraocular inflammation, have been reported and require prompt evaluation; treatment should be discontinued if these events occur. Because faricimab inhibits VEGF pathways, a potential risk of arterial thromboembolic events should also be considered. Patients should be instructed to report sudden visual changes, significant eye pain, redness, or light sensitivity without delay.

Before treatment, patients should undergo an appropriate ophthalmic examination, including assessment of visual acuity and retinal anatomy, with optical coherence tomography or other imaging when clinically indicated. Ocular or periocular infection and active intraocular inflammation should be excluded before injection. Intraocular pressure should be monitored when appropriate, particularly in patients with glaucoma or other risk factors for pressure elevation. Pregnancy and breastfeeding considerations should be reviewed individually because human pregnancy data are limited. Faricimab is administered locally into the eye and therefore has limited systemic exposure compared with systemic monoclonal antibody treatment, so classic drug interactions are not generally a major concern. However, concurrent intravitreal treatments and ocular procedures should be coordinated carefully. Patients with a history of arterial thromboembolic events or significant cardiovascular or cerebrovascular disease should be assessed individually because of the potential systemic risks associated with VEGF inhibition.

Confirm the retinal diagnosis and assess baseline visual acuity, retinal anatomy, disease activity, intraocular pressure, and the presence of infection or active inflammation before treatment. Use strict aseptic technique for every intravitreal injection and ensure that administration is performed by an appropriately trained ophthalmic professional. Follow the applicable product storage, preparation, and handling requirements and use a single-dose presentation for one eye only. After injection, monitor intraocular pressure when appropriate and counsel patients to report eye pain, increasing redness, photophobia, sudden visual deterioration, or new floaters promptly. During long-term therapy, use visual acuity and retinal imaging findings to guide individualized dosing intervals. Review treatment response regularly and coordinate care with other retinal therapies when required. In patients with cardiovascular or cerebrovascular risk factors, consider the potential systemic effects of VEGF inhibition as part of the overall clinical assessment.